Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

Published:2014-05-29 Issue:5 Volume:5 Page:475-477
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Invest

Author:

Yabe Daisuke¹²³,Seino Yutaka¹

Affiliation:

1. Center for Diabetes Endocrinology and Metabolism Osaka Japan

2. Center for Metabolism and Clinical Nutrition Kansai Electric Power Hospital Osaka Japan

3. Division of Molecular and Metabolic Medicine Kobe University Graduate School of Medicine Kobe Japan

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.12229

Reference5 articles.

1. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

2. Exendin-4 Suppresses Src Activation and Reactive Oxygen Species Production in Diabetic Goto-Kakizaki Rat Islets in an Epac-Dependent Manner

3. Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic β-cells

4. The cAMP Sensor Epac2 Is a Direct Target of Antidiabetic Sulfonylurea Drugs

5. Antidiabetic Sulfonylureas and cAMP Cooperatively Activate Epac2A

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases;Ageing Research Reviews;2023-11

2. Pharmacologic Heterogeneity and Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and DPP‐4 Inhibitors: Population‐Based Cohort Study;Clinical Pharmacology & Therapeutics;2023-07

3. Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes;Endocrinology and Metabolism;2023-02-28

4. Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70);Journal of Diabetes Investigation;2022-10-21

5. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan;Advances in Therapy;2022-02-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3